Case report

Cushing’s syndrome with suppression of the hypothalamic-pituitary-adrenal axis after intra-articular steroid injections

M M O’SULLIVAN, W R RUMFELD, M K JONES, AND B D WILLIAMS

From the Departments of Rheumatology and Medicine, University Hospital of Wales, Heath Park, Cardiff CF4 4XW

SUMMARY A case of Cushing’s syndrome after long term intra-articular corticosteroid injections is described. Prolonged suppression of the hypothalamic-pituitary-adrenal axis occurred as assessed by an insulin tolerance test 11 weeks after the last intra-articular injection. Replacement steroid therapy was required.

Key words: intra-articular corticosteroids.

Intra-articular corticosteroid injections for rheumatic conditions were first introduced by Hollander in 1951. Hydrocortisone acetate was the first intra-articular preparation used but has been replaced by a number of synthetic steroid derivatives whose duration of action is much longer. Studies comparing the relative efficacy of these agents have shown that the duration of response correlates inversely with the solubility of the preparation in water, the least soluble triamcinolone hexacetonide having the longest action. Steroid absorbed from the synovial cavity induces systemic effects, including diminished joint swelling at sites distant from the injected joint and transient eosinopenia. Estimation of plasma levels of synthetic steroids after intra-articular injection has confirmed their systemic absorption. A single report records possible iatrogenic Cushing’s syndrome after repeated local steroid injections in a patient with rheumatoid arthritis.

In this communication we report a patient with rheumatoid arthritis who developed iatrogenic Cushing’s syndrome with prolonged suppression of the hypothalamic-pituitary-adrenal axis after long term administration of intra-articular triamcinolone hexacetonide.

Case report

A 59-year-old male, who developed seropositive rheumatoid arthritis in 1976, was referred to our clinic in May 1984 for investigation of muscle weakness. Early on in the course of his disease he had received treatment with Myocrisin and penicillamine, but both drugs were discontinued because of the development of side effects. Rheumatoid involvement of his shoulders and knees was particularly severe, and for eight years he was given intra-articular injections of triamcinolone hexacetonide 300 mg divided equally between the four joints and given at eight-weekly intervals. For several years his joint symptoms were well controlled by the intra-articular injections, but in the three years before attendance at our clinic the nature of his symptoms changed. His appetite was poor and he became easily tired and lethargic. These symptoms appeared five weeks after steroid injection but disappeared within hours of the next intra-articular injection.

The patient is shown in Fig. 1. He had truncal obesity with pronounced buffalo hump. On examination he had thin skin and bruising with general and palmar crease pigmentation. Muscle wasting...
hourly for 72 hours did not produce an increase in the 24-hour excretion of 17-hydroxycorticosteroids (17-OHCS) (Table 2).

The changes in plasma glucose, prolactin, growth hormone, and cortisol levels during the insulin tolerance test are shown in Table 3. The fall in plasma glucose was sufficient to produce symptoms of hypoglycaemia. The expected rise in plasma prolactin occurred, there was some impairment in the growth hormone response (normal > 20 IU/l), and there was no change in the plasma cortisol levels. After endocrine assessment our patient was discharged on replacement therapy (prednisone 2.5 mg twice daily), which abolished his previous symptoms of lethargy and malaise.

**Discussion**

Intra-articular corticosteroid injections are a valuable adjunct in the management of rheumatoid arthritis especially when active disease is confined to a few joints. At a dose range which varies between 10 and 40 mg intra-articular injections of triamcinolone hexacetonide generally produce a sustained improvement in patient symptoms. Our patient received twice the recommended dose into the knees and shoulders, and because of a favourable response the injections were continued at weekly intervals for a period of seven years. It became apparent, however, that during the last three years intra-articular steroids were necessary to reverse the general symptoms which had developed as a result of hypothalamic-pituitary-adrenal suppression.

An assessment of his hypothalamic-pituitary-adrenal axis was carried out 11 weeks after the last injection of triamcinolone hexacetonide. The 0900 hour plasma cortisol was less than 28 nmol/l. The plasma cortisol response to 1 mg of Synacthen Depot (tetracosactrin) given at 0900 hours was normal, with a peak value at eight hours of 622 nmol/l (Table 1). Metyrapone 250 mg given two hourly for 72 hours did not produce an increase in the 24-hour excretion of 17-hydroxycorticosteroids (17-OHCS) (Table 2).

**Table 1** Long Synacthen test (1 mg Synacthen Depot (tetracosactrin) given at 0900 hours)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Plasma cortisol (nmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>102</td>
</tr>
<tr>
<td>6</td>
<td>518</td>
</tr>
<tr>
<td>8</td>
<td>622</td>
</tr>
<tr>
<td>24</td>
<td>584</td>
</tr>
<tr>
<td>48</td>
<td>116</td>
</tr>
</tbody>
</table>

**Table 2** Metyrapone 250 mg given two hourly for 72 hours

<table>
<thead>
<tr>
<th>17-OHCS excretion (mg/24 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal rate</td>
</tr>
<tr>
<td>Day 1</td>
</tr>
<tr>
<td>Day 2</td>
</tr>
<tr>
<td>Day 3</td>
</tr>
</tbody>
</table>

and weakness of his shoulder girdles and pelvic girdle muscles was evident, though the weakness at the shoulder girdles could be attributed in part to the limited range of movement present at these joints. The laboratory investigations were as follows: haemoglobin 14.8 g/dl, erythrocyte sedimentation rate 84 mm/h (Westergren), sodium 138 mmol/l, potassium 4.2 mmol/l, urea 5.1 mmol/l, rheumatoid factor titre 1/2048, antinuclear factor negative, blood glucose 8.4 mmol/l, free thyroxine 18 pmol/l (normal range 8–26 pmol/l), creatine phosphokinase 26 IU/l (normal range 0–130 IU/l). Skull x-ray was normal.

Fig. 1 *The patient.*

An assessment of his hypothalamic-pituitary-adrenal axis was carried out 11 weeks after the last injection of triamcinolone hexacetonide. The 0900 hour plasma cortisol was less than 28 nmol/l. The plasma cortisol response to 1 mg of Synacthen Depot (tetracosactrin) given at 0900 hours was normal, with a peak value at eight hours of 622 nmol/l (Table 1). Metyrapone 250 mg given two

...
Transient suppression of the hypothalamic-pituitary-adrenal axis, as shown by low 0900 hour plasma cortisol levels, has been reported up to six days after intra-articular steroid injections. In one study of intra-articular injection of methylprednisolone the plasma cortisol was suppressed by 64–81% 24 hours after the injection. This effect of a single dose remained for three days, and the serum cortisol was restored to normal after one week. Sustained suppression, however, has not previously been reported. In this patient the adrenal suppression was still evident 11 weeks after the last intra-articular steroid injection and was sufficiently severe to be associated with clinical features of cortisol deficiency. The circumstances which led to this suppression were unusual and it is not known whether there would be any significant prolonged adrenal suppression if more conventional doses were given less frequently to patients. The possibility of hypothalamic-pituitary-adrenal axis suppression should, however, be considered in patients who have received repeated intra-articular steroid injections. This is obviously important, as these patients may not respond appropriately to the stress of surgery/trauma or acute medical illness and may require replacement therapy to avoid an adrenal crisis.

### References
Cushing's syndrome with suppression of the hypothalamic-pituitary-adrenal axis after intra-articular steroid injections.

M M O'Sullivan, W R Rumfeld, M K Jones and B D Williams

*Ann Rheum Dis* 1985 44: 561-563
doi: 10.1136/ard.44.8.561

Updated information and services can be found at:

http://ard.bmj.com/content/44/8/561

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/